Innovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial
CompanyDrug

Innovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial

Dizal Pharmaceutical Reports Strong Revenue Growth in 2024 and Q1 2025
Company

Dizal Pharmaceutical Reports Strong Revenue Growth in 2024 and Q1 2025

Ipsen and Shanghai Pharmaceutical Partner to Expand Diphereline Coverage in China
CompanyDeals

Ipsen and Shanghai Pharmaceutical Partner to Expand Diphereline Coverage in China

Novartis Q1 2025 Results: Net Sales Up 15% YOY, Strong Growth in Key Brands
Company

Novartis Q1 2025 Results: Net Sales Up 15% YOY, Strong Growth in Key Brands

Merck Sharp & Dohme Announces $1 Billion Biologics Center in Wilmington, Delaware
Company

Merck Sharp & Dohme Announces $1 Billion Biologics Center in Wilmington, Delaware

Eli Lilly Partners with Creyon Bio to Develop RNA-Targeted Therapies
CompanyDeals

Eli Lilly Partners with Creyon Bio to Develop RNA-Targeted Therapies

AbbVie's Rinvoq Gains FDA Approval for Giant Cell Arteritis
CompanyDrug

AbbVie’s Rinvoq Gains FDA Approval for Giant Cell Arteritis

Bayer AG Launches Phase I Study of 225Ac-GPC3 for Advanced Hepatocellular Carcinoma
CompanyDrug

Bayer AG Launches Phase I Study of 225Ac-GPC3 for Advanced Hepatocellular Carcinoma

Itcure and OBiO Technology Partner to Advance Gene Editing and VLP Delivery Systems
CompanyDeals

Itcure and OBiO Technology Partner to Advance Gene Editing and VLP Delivery Systems

Fosun Pharma Partners with Fakeeh Care Group to Advance Biopharmaceuticals in Saudi Arabia
CompanyDeals

Fosun Pharma Partners with Fakeeh Care Group to Advance Biopharmaceuticals in Saudi Arabia

Fosun Pharma Reports Q1 2025 Revenues of RMB 9.42 Billion, Net Profits of RMB 765 Million
Company

Fosun Pharma Reports Q1 2025 Revenues of RMB 9.42 Billion, Net Profits of RMB 765 Million

Roche's VENTANA TROP2 Device Receives FDA Breakthrough Designation
CompanyMedical Device

Roche’s VENTANA TROP2 Device Receives FDA Breakthrough Designation